At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
AZD1656 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients
In Brief
A Phase 2 clinical trial evaluating AZD1656 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 224 participants across 3 sites.
Detailed Summary
The purpose of this study is to compare the effect on glucose control of 3 different AZD1656 dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as evaluated by the change in HbA1c from baseline to the end of treatment at 4 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedJun 29, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.0 years ago
Interventions
AZD1656drug
Oral tablet administered twice daily during 4 months
Placebodrug
administered twice daily during 4 months